Belite Bio Eyes FDA Decision as Stargardt Drug Could Unlock $7B Market

Belite Bio (NASDAQ:BLTE) executives said the company is advancing toward a potential U.S. approval decision for tinlarebant, its oral once-daily treatment for Stargardt disease, while also preparing for broader development in geographic atrophy.

Speaking at the Bank of America Healthcare Conference, Chief Executive Officer Tom Lin described Belite as an ophthalmology- and retinal-focused company that spun out of Lin BioScience in 2018 and listed publicly in 2022. Lin said the company’s clinical programs have progressed “pretty smooth” and that management sees “a lot of potential” in its lead drug candidate.

Stargardt Disease Program Advances Through FDA Review

Chief Scientific Officer Nathan Mata said Stargardt disease is a monogenic inherited retinal disease with autosomal recessive inheritance. He estimated prevalence at roughly one in 6,000 people, or about 53,000 patients in the U.S. Mata said the disease is particularly devastating in children because early visual acuity loss can affect education, social development and long-term socioeconomic outcomes.

Mata said tinlarebant, an oral once-daily tablet, has shown the ability to reduce lesion growth by as much as 36% over a two-year period in Stargardt patients. He said that level of efficacy had “never been seen before” in a clinical study of Stargardt disease or geographic atrophy.

The company’s pivotal Phase 3 DRAGON trial enrolled 104 patients globally and randomized them 2-to-1 in favor of tinlarebant. Patients received a 5 mg tablet once daily in a two-year study, with assessments of lesion growth, visual function and safety. Mata said an interim analysis conducted after all patients reached 12 months led the data safety monitoring board to recommend that Belite submit the data for regulatory review. The company subsequently received Breakthrough Therapy designation.

Mata said Belite has begun a rolling submission of its U.S. application. The company started submitting modules on April 21 and expects to complete the process in early to mid-June. He said the FDA would then have 60 days to assess the application’s appropriateness, followed by a six-month period for a final approval decision if accepted under Priority Review.

Management Sees Single-Study Approval Path Remaining Intact

Asked about turnover at the FDA, Mata said the company does not expect recent leadership changes to alter its day-to-day interactions with the agency. He said Belite has had a path supported by FDA officials for filing based on a single Phase 3 study with confirmatory evidence, particularly in an orphan disease such as Stargardt.

Lin said Belite had worked with the FDA early in development and had received Rare Pediatric Disease designation, adding that the clinical trial was designed to satisfy agency requirements. “It has been a pretty smooth path, and I think the data speaks for itself,” Lin said.

Mata also said the drug’s safety profile appears “very clean,” noting that the overall dropout rate in the study was less than 10% over two years. He said physicians have responded positively to the prospect of an oral treatment in a disease where patients currently have few options beyond measures such as avoiding bright sunlight and wearing sunglasses.

Commercial Planning Focuses on Rare Disease Pricing and Targeted Launch

Hao-Yuan Chuang, Belite’s chief financial officer, said it is still early to provide a definitive price range, but he referenced U.S. rare disease pricing of about $350,000 per year and said the company believes it could potentially price tinlarebant between $400,000 and $500,000 annually while balancing payer considerations.

Chuang said Belite expects to launch with a commercial footprint of about 30 people, including diagnostic and sales personnel, with the potential to roughly double that size within two years. He said the launch strategy would focus on reminding physicians and patients that a treatment is available and encouraging testing to support coverage.

Chuang said that, assuming roughly one-third of the estimated 53,000 U.S. Stargardt patients receive treatment at a price of $400,000 to $500,000 per year, the U.S. opportunity could reach approximately $7 billion in peak sales. Lin said about 10,000 patients may already be actively managed by retinal specialists, and he expects patient advocacy groups and specialty centers to help identify eligible patients.

Company Says Competitive Threats Are Years Away

Mata said Belite does not believe any competitor is within five years of being competitive in the Stargardt market. He cited other oral therapies, RNAi approaches and gene-based strategies, but said recruiting trials could become more difficult if tinlarebant is approved and becomes available. He also noted that more than 2,000 mutations are associated with Stargardt disease, which could complicate mutation-specific therapeutic approaches.

Lin said the 36% efficacy result in DRAGON sets a “pretty high bar” for future competitors, especially in a neurodegenerative disease. He said other companies attempting to match that level of efficacy could require substantially larger trials, particularly if tinlarebant becomes the standard of care.

Geographic Atrophy Readout Targeted for Year-End

Belite is also developing tinlarebant for geographic atrophy, a later-stage form of age-related macular degeneration. Mata said the rationale comes from earlier work showing that reducing retinol binding protein 4, or RBP4, can slow lesion growth. Tinlarebant is designed to reduce vitamin A delivery to the eye by targeting RBP4.

Mata said the company does not expect a visual acuity benefit in a two-year trial because vision loss in these diseases can be slow, making lesion growth a more practical and reproducible endpoint. He said an oral drug with similar efficacy to currently approved injectable geographic atrophy therapies could be attractive because of lower treatment burden.

Lin said Belite is aiming for an interim geographic atrophy data readout by the end of the year. Mata said the study enrolled 530 patients, while Chuang said the company has not yet confirmed details of the study design and would provide more information once finalized.

About Belite Bio (NASDAQ:BLTE)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.